DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: sildenafil citrate

Summary for Generic Name: sildenafil citrate

Tradenames:3
Patents:1
Applicants:11
NDAs:13
Drug Master File Entries: see list18
Suppliers: see list10
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: sildenafil citrate

Tentative approvals for SILDENAFIL CITRATE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL25MG
<disabled><disabled>TABLET; ORAL50MG
<disabled><disabled>TABLET; ORAL100MG

Clinical Trials for: sildenafil citrate

A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions
Status: Completed Condition: Pulmonary Arterial Hypertention

A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
Status: Not yet recruiting Condition: Erectile Dysfunction

Sildenafil for Prevention of Cerebral Vasospasm
Status: Recruiting Condition: Subarachnoid Hemorrhage; Cerebral Vasospasm; Rupture of Intracranial Aneurysm

Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?
Status: Recruiting Condition: Pulmonary Hypertension

Bioequivalence Study For Orally-Disintegrating Tablet Of Sildenafil
Status: Completed Condition: Healthy

Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.
Status: Completed Condition: Erectile Dysfunction

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pfizer
REVATIO
sildenafil citrate
FOR SUSPENSION;ORAL203109Aug 30, 2012RXYes<disabled>NEW DOSAGE FORM
Pfizer
REVATIO
sildenafil citrate
FOR SUSPENSION;ORAL203109Aug 30, 2012RXYes<disabled>PEDIATRIC EXCLUSIVITY
Pfizer
REVATIO
sildenafil citrate
FOR SUSPENSION;ORAL203109Aug 30, 2012RXYes<disabled>
Pfizer
REVATIO
sildenafil citrate
SOLUTION;INTRAVENOUS022473Nov 18, 2009RXYes<disabled>REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc